• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

    8/10/23 8:54:25 AM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email
    SC 13D/A 1 d539259dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 11)*

     

     

    AMYRIS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    03236M200

    (CUSIP Number)

    Barbara Hager

    c/o Foris Ventures, LLC

    1180 San Carlos Avenue, #717

    San Carlos, CA 94070

    650-384-0240

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    COPY TO:

    Jon M. Novotny, Esq.

    c/o Goodwin Procter LLP

    Three Embarcadero Center

    San Francisco, CA 94111

    (415) 733-6000

    August 9, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAME OF REPORTING PERSON

     

      Foris Ventures, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      120,499,897(1)

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      120,499,897(1)

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,499,897(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of (i) 87,268,358 shares of common stock, par value $0.0001 per share (“Common Stock”), of Amyris, Inc. (the “Company”) currently outstanding and held by Foris Ventures, LLC (“FV”), (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the total amount of indebtedness outstanding, including accrued and unpaid interest as of August 9, 2023, under that certain Amended and Restated Loan and Security Agreement, dated as of October 28, 2019 (as it may be further amended, restated or otherwise modified, the “2019 LSA”), by and among the Company, FV, as lender, and the other parties thereto; (iii) 2,046,036 shares of Common Stock issuable to FV upon exercise of a warrant issued to FV on September 13, 2022 (the “September 2022 Warrant”) in connection with that certain Loan and Security Agreement, dated as of September 13, 2022 (as it may be amended, restated or otherwise modified, the “2022 LSA”), by and among the Company, FV, as lender, and the other parties thereto; and (iv) 10,000,000 shares of Common Stock issuable to FV upon exercise of a warrant issued to FV on December 30, 2022 (the “December 2022 Warrant” and together with the September 2022 Warrant, collectively the “2022 Warrants”). As of August 9, 2023, 16,680,334 shares of Common Stock are issuable upon conversion of the indebtedness outstanding under the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,505,169 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.5 million, reflecting a fixed conversion price of $3.00 per share of Common Stock. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of these securities. The 2019 LSA bears interest at 6.0% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA; interest accrues until the maturity date of July 1, 2024. The Vallejo Ventures Trust U/T/A 2/12/96 (“VVT”), the member of FV, may be deemed to have sole power to vote and dispose of these securities, and L. John Doerr (“John Doerr”) and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of these securities.     

    (2)

    The percentage calculation is based on a total of 402,617,153 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      The Vallejo Ventures Trust U/T/A 2/12/96

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      120,500,464(1)

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      120,500,464(1)

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,500,464(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants and (iv) 567 shares of Common Stock held directly by VVT. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,617,153 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      L. John Doerr

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      140,711(1)

         8  

      SHARED VOTING POWER

     

      124,096,280(2)

         9  

      SOLE DISPOSITIVE POWER

     

      140,711(1)

       10  

      SHARED DISPOSITIVE POWER

     

      124,096,280(2)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      124,236,991(3)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      30.9%(4)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 46,047 shares of Common Stock held by John Doerr, (ii) 14,664 shares of Common Stock issuable to John Doerr upon exercise of options within 60 days of August 9, 2023 and (iii) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 9, 2023.

    (2)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC, (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, and (viii) 3,333,333 shares of Common Stock held by Perrara Ventures, LLC (“Perrara”). John Doerr is a trustee of VVT, which is the member of FV and Clarus, LLC. Mr. Doerr may be deemed to have shared power to vote and dispose of shares beneficially owned by FV, VVT and Clarus, LLC. The Managing Member of Kleiner Perkins Caufield & Byers XII, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. The Managing Member of KPCB XII Founders Fund, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. Mr. Doerr indirectly holds all of the membership interests in Perrara. Mr. Doerr disclaims beneficial ownership of all securities held by entities affiliated with him except to the extent of his pecuniary interest therein.

    (3)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC, (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, (viii) 3,333,333 shares of Common Stock held by Perrara, (ix) 46,047 shares of Common Stock held by John Doerr, (x) 14,664 shares of Common Stock issuable to Mr. Doerr upon exercise of options within 60 days of August 9, 2023, and (xi) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 9, 2023. John Doerr is a trustee of VVT, which is the member of FV and Clarus, LLC. Mr. Doerr may be deemed to have shared power to vote and dispose of shares beneficially owned by FV, VVT and Clarus, LLC. The Managing Member of Kleiner Perkins Caufield & Byers XII, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. The Managing Member of KPCB XII Founders Fund, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. Mr. Doerr indirectly holds all of the membership interests in Perrara. Mr. Doerr disclaims beneficial ownership of all securities held by entities affiliated with him except to the extent of his pecuniary interest therein.

    (4)

    The percentage calculation is based on a total of 402,711,817 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 14,664 shares of Common Stock issuable to John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of August 9, 2023, and (v) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 9, 2023.


      1    

      NAME OF REPORTING PERSON

     

      Ann Doerr

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      120,500,464(1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      120,500,464(1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,500,464(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants and (iv) 567 shares of Common Stock held directly by VVT. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,617,153 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      Barbara Hager

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      123,843,445(1)

         8  

      SHARED VOTING POWER

     

      0

         9  

      SOLE DISPOSITIVE POWER

     

      123,843,445(1)

       10  

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      123,843,445(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      30.8%(2)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held directly by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, and (vi) 3,333,333 shares of Common Stock held by Perrara. Barbara Hager, the manager of FV and Clarus, LLC, may be deemed to have sole power to vote and dispose of these securities. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,617,153 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


    This Amendment No. 11 (“Amendment No. 11”) to Schedule 13D amends the statement on Schedule 13D filed with the United States Securities and Exchange Commission on October 30, 2017, as amended by Amendment No. 1 thereto filed on August 28, 2018, Amendment No. 2 thereto filed on July 18, 2019, Amendment No. 3 thereto filed on September 8, 2022, Amendment No. 4 thereto filed on September 15, 2022, Amendment No. 5 thereto filed on January 9, 2023, Amendment No. 6 thereto filed on March 17, 2023, Amendment No. 7 thereto filed on May 24, 2023, Amendment No. 8 thereto filed on June 9, 2023, Amendment No. 9 thereto filed on June 30, 2023 and Amendment No. 10 thereto filed on August 3, 2023 (collectively and as amended, the “Schedule 13D”), relating to the Common Stock. This Amendment No. 11 is being filed by Foris Ventures, LLC, Vallejo Ventures Trust, L. John Doerr, Ann Doerr, and Barbara Hager (collectively, the “Reporting Persons”).

    The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 11 does not modify any of the information previously reported in the Schedule 13D.

     

    ITEM 4.

    PURPOSE OF TRANSACTION.

    Item 4 of the Schedule 13D is supplemented by the following:

    Bankruptcy Petition; DIP Credit Agreement

    On August 9, 2023 (the “Petition Date”), the Company and certain of its direct and indirect subsidiaries (collectively, the “Company Parties” or the “Debtors”) filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing Chapter 11 cases for the Company Parties (the “Chapter 11 Cases”). On the Petition Date, the Company Parties filed a motion with the Bankruptcy Court seeking to jointly administer the Chapter 11 Cases under the caption “In re: Amyris, et al.”

    The Company Parties are seeking approval of various “first day” motions with the Bankruptcy Court, requesting customary relief intended to enable them to continue their ordinary course operations and facilitate an orderly transition of their operations into Chapter 11. In addition, the Company Parties filed with the Bankruptcy Court a motion seeking approval (“Interim DIP Order”) of debtor-in-possession financing (“DIP Financing”) in the form of the DIP Credit Agreement (as defined and described below).

    As discussed above, the Company Parties have sought an order authorizing the Company, Amyris Clean Beauty, Inc., and Aprinnova, LLC, in their capacity as borrowers (collectively, the “Borrowers”), to obtain post-petition financing, and for each of the other Debtors and certain other non-Debtor subsidiaries (the “Guarantors”) to guarantee unconditionally on a joint and several basis, the Borrowers’ obligations in connection with a senior secured super-priority multiple-draw term loan facility (the “DIP Facility”) in the aggregate principal amount of up to $190 million, subject to and in accordance with the terms and conditions set forth in that certain Senior Secured Super Priority Debtor In Possession Loan Agreement, dated as of August 9, 2023 (the “DIP Credit Agreement”), by and among the Borrowers, the Guarantors, Euagore, LLC, an affiliate of Foris Ventures, LLC (and such other lenders from time to time party thereto, the “Lenders”), and Euagore, LLC, as Administrative Agent (the “Administrative Agent”). The proceeds of the proposed DIP Facility may be used for, among other things, post-petition working capital for the Company and its subsidiaries, payment of costs to administer the Chapter 11 Cases, payment of expenses and fees of the transactions contemplated by the Chapter 11 Cases and payment of other costs, in each case, subject to an approved budget and such other purposes permitted under the DIP Credit Agreement and the Interim DIP Order.

    The DIP Credit Agreement includes certain required milestones with respect to the Chapter 11 Cases, including, but not limited to, a requirement that no later than thirty-five (35) days after the Petition Date, the Debtors shall have executed a plan support agreement (the “Plan Support Agreement”), by and among the Debtors, the Administrative Agent, the Lenders, the other pre-petition secured lenders of the Company and certain other parties, which is acceptable to the Lenders and such other pre-petition secured lenders of the Company that are affiliates of FV, in their sole discretion (such milestone, the “Plan Support Agreement Milestone”). If the Plan Support Agreement Milestone is not satisfied on or prior to the applicable deadline, the Administrative Agent, in its sole discretion, may elect to require the Debtors to initiate a process to market and sell all of the Company’s assets.


    The DIP Credit Agreement is subject to approval by the Bankruptcy Court. The Company disclosed that it has requested authorization from the Bankruptcy Court, upon entry of the Interim DIP Order, for no more than two draws prior to the entry of a final order approving the DIP Financing (the “Final DIP Order”), in the aggregate principal amount of up to $70 million; and upon entry of the Final DIP Order, multiple additional draws in the aggregate principal amount not to exceed $120 million. The Company further disclosed that it has requested a hearing on or before August 11, 2023, to consider entry of the Interim DIP Order and stated that it anticipates that the DIP Credit Agreement will become effective promptly following entry of the Interim DIP Order by the Bankruptcy Court.

    The Company disclosed that it cannot be certain that holders of the Company’s Common Stock will receive any payment or other distribution on account of those shares following the Chapter 11 Cases. The Company further stated that it expects to receive a notice from The Nasdaq Stock Market (“Nasdaq”) that the Common Stock is no longer suitable for listing pursuant to Nasdaq Listing Rule 5110(b) as a result of the Chapter 11 Cases. If the Company receives such notice, the Company stated that it does not intend to appeal Nasdaq’s determination and, therefore, the Company expects that the Common Stock will be delisted.

    Default under Existing Debt Arrangements

    The commencement of the Chapter 11 Cases described above constitutes an event of default that accelerated the Company’s obligations under certain debt instruments by and between the Company, certain subsidiaries of the Company and the Reporting Parties (or affiliates of the Reporting Parties), among other debt instruments issued by the Company, including but not limited to:

     

      •  

    the 2019 LSA;

     

      •  

    the 2022 LSA;

     

      •  

    the Loan and Security Agreement, dated as of March 10, 2023, by and among the Company, certain other Company Parties and Perrara Ventures, LLC;

     

      •  

    the Loan and Security Agreement, dated as of June 5, 2023, by and among the Company, certain other Company Parties and Anesma Group, LLC;

     

      •  

    the Loan and Security Agreement, dated as of June 29, 2023, by and among the Company, certain other Company Parties and Anjo Ventures, LLC; and

     

      •  

    the Loan and Security Agreement, dated as of August 2, 2023, by and among the Company, certain other Company Parties and Muirisc, LLC;

    each as amended, restated, supplemented or otherwise modified from time to time (collectively, the “Debt Instruments”).

    The Debt Instruments provide that as a result of the Chapter 11 Cases, the principal and interest due thereunder shall be immediately due and payable, among other things. Any efforts to enforce such payment obligations under the Debt Instruments are automatically stayed as a result of the Chapter 11 Cases, and the creditors’ rights of enforcement in respect of the Debt Instruments are subject to the applicable provisions of the Bankruptcy Code.

    General

    The Reporting Persons acquired the securities described in this Schedule for investment purposes and they intend to review their investments in the Company on a continuing basis. In addition, the Reporting Persons intend to participate in the management of the Company through representation on the Company’s board of directors (the “Board”). L. John Doerr and Ryan Panchadsaram, a partner at Foris Ventures, serve as members of the Board. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Company’s business, financial condition, operations and prospects, including with respect to the Chapter 11 Cases; price levels of the Company’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.


    The Reporting Persons have been in discussion with members of the Company’s management and Board in connection with the Chapter 11 Cases and other strategic alternatives and may continue to be in contact with members of the Company’s management, members of the Board, shareholders, advisors and other relevant parties regarding any alternatives that the Company could employ in the Chapter 11 Cases or otherwise. The Reporting Persons may take positions with respect to potential changes in the operations, management, Board composition, ownership, capital structure, strategy and future plans of the Company. In addition to its role with respect to the DIP Credit Agreement, the Reporting Persons may consider participating in transactions that are part of the Chapter 11 Cases, including as part of the Company’s reorganization efforts and/or sales of significant Company assets. The Reporting Persons may also, at any time and from time to time, acquire additional securities of the Company, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition to the items described above in this Item 4, the Reporting Persons may take one or more other actions that relate to or would result in any other matter referenced in items (a) through (j) of Item 4 of Schedule 13D, alone or with others, including other shareholders or creditors of the Company or other appropriate parties, although the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

     

    ITEM 5.

    INTEREST IN SECURITIES OF THE ISSUER.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a)-(b)

    The following sets forth, as of the date of this statement, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on a total of 402,617,153 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.

    For the purposes of calculating John Doerr’s beneficial ownership only, the percent of class set forth below is based on a total of 402,711,817 based on the Company’s shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,185,503 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 14,664 shares of Common Stock issuable to John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of August 9, 2023, and (v) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 9, 2023.

     

    Reporting

    Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole
    power to
    vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct
    the vote
         Sole
    power to
    dispose or
    to direct
    the disposition
         Shared
    power to
    dispose or
    to direct
    the disposition
     

    FV

         120,499,897        29.9 %      120,499,897        0        120,499,897        0  

    VVT

         120,500,464        29.9 %      120,500,464        0        120,500,464        0  

    John Doerr

         124,236,991        30.9 %      140,711        124,096,280        140,711        124,096,280  

    Ann Doerr

         120,500,464        29.9 %      0        120,500,464        0        120,500,464  

    Barbara Hager

         123,843,445        30.8 %      123,843,445        0        123,843,445        0  

    The securities reported herein consist of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,185,503 shares of Common Stock issuable upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 9, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield &


    Byers XII, LLC and (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, (viii) 3,333,333 shares of Common Stock held by Perrara, (ix) 46,047 shares of Common Stock held by John Doerr, (x) 14,664 shares of Common Stock issuable to John Doerr upon exercise of options within 60 days of August 9, 2023, and (xi) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 9, 2023.

    As of August 9, 2023, 16,680,334 shares of Common Stock are issuable upon conversion of the indebtedness outstanding under the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,505,169 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.5 million, reflecting a fixed conversion price of $3.00 per share of Common Stock. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of these securities. The 2019 LSA bears interest at 6.0% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA; interest is not payable until the maturity date of July 1, 2024.

     

      (c)

    On June 30, 2023, 11,600 restricted stock units previously granted to Mr. Doerr in his capacity as a director of the Company vested in accordance with their terms.

    On August 1, 2023, options to purchase 400 shares of Common Stock previously granted to Mr. Doerr in his capacity as a director of the Company expired for no consideration in accordance with their terms.

    Other than as set forth in this Item 5, the Reporting Persons have not effected any transaction in the Common Stock during the past 60 days.

     

      (d)

    Except as set forth in Item 4 above, no person is known to have the right to receive dividends from, or the proceeds from, the sale of shares identified pursuant to Item 1.

     

      (e)

    Not applicable.

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The information set forth under Items 4 and 5 and the agreements set forth on the Exhibit attached hereto are incorporated herein by reference. Other than as described herein and in the Schedule 13D, to the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between each Reporting Person and any person, with respect to the securities of the Company, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

     

    ITEM 7.

    MATERIAL TO BE FILED AS EXHIBITS.

    Item 7 of the Schedule 13D is hereby supplemented as follows:

     

    Exhibit

      

    Description

    PP    Senior Secured Super Priority Debtor In Possession Loan Agreement, dated as of August 9, 2023, by and among the Borrowers, the Guarantors and Euagore, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 10, 2023).


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: August 10, 2023

     

    FORIS VENTURES, LLC
    By:   /s/ Barbara Hager
    Name:   Barbara Hager
    Title:   Manager
    VALLEJO VENTURES TRUST
    By:   /s/ Barbara Hager
    Name:   Barbara Hager
    Title:   Special Trustee
    L. JOHN DOERR
    By:   /s/ L. John Doerr, by Barbara Hager as his attorney in fact
    ANN DOERR
    By:   /s/ Ann Howland Doerr, by Barbara Hager as her attorney in fact
    BARBARA HAGER
    By:   /s/ Barbara Hager
    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $AMRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider White J. Scott

      3 - AMYRIS, INC. (0001365916) (Issuer)

      9/20/23 8:09:50 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Gund Philip J.

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:35:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Reiss M. Freddie

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:32:49 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:14:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:12:50 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

      Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

      8/9/23 9:38:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Leadership Updates

    Live Leadership Updates

    See more

    $AMRS
    Financials

    Live finance-specific insights

    See more

    $AMRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $AMRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

      EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re

      1/27/22 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

      EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

      5/2/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

      Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

      3/15/23 4:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

      EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

      2/28/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      1/5/24 4:22:57 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      12/14/23 4:34:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      10/16/23 4:41:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials